Literature DB >> 11250928

Inability of overexpressed des(1-3)human insulin-like growth factor I (IGF-I) to inhibit forced mammary gland involution is associated with decreased expression of IGF signaling molecules.

D L Hadsell1, T Alexeenko, Y Klimentidis, Y Klemintidis, D Torres, A V Lee.   

Abstract

Overexpression of des(1-3) human insulin-like growth factor I (IGF-I) in the mammary glands of transgenic mice (WAP-DES) inhibits apoptosis during natural, but not forced, mammary involution. We hypothesized that this differential response would correlate with the expression of IGF signal transducers. Forced and natural involution were analyzed in nontransgenic and WAP-DES mice beginning on day 16 postpartum. During natural involution, mammary gland wet weight was higher and apoptosis was lower in WAP-DES than in nontransgenic mice. The WAP-DES transgene had no effect on these parameters during forced involution. Mammary tissue concentrations of the transgene protein were 2- to 10-fold higher than those of endogenous IGF-I. Western blot analysis of pooled mammary tissue extracts demonstrated only slightly higher phosphorylation of the IGF signal transducers insulin receptor substrate-1 (IRS-1) and Akt in the WAP-DES than in nontransgenic mice. Dramatic early reductions in phospho-IRS-1, phospho-Akt, IRS-1, IRS-2, and Akt proteins occurred during forced, but not natural, involution. The abundance of the IGF-I receptor and the messenger RNAs for the IGF-I receptors, IRS-1 and -2, were not affected by either genotype or involution. These findings support the conclusions that mammary cells lose their responsiveness to insulin-like signals during forced involution, and that posttranscriptional or posttranslational regulation of IRS-1 and IRS-2 may play a role in this loss.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11250928     DOI: 10.1210/endo.142.4.8087

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis.

Authors:  Shauntae M McDaniel; Kristen K Rumer; Sandra L Biroc; Richard P Metz; Meenakshi Singh; Weston Porter; Pepper Schedin
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 2.  Postpartum Involution and Cancer: An Opportunity for Targeted Breast Cancer Prevention and Treatments?

Authors:  Virginia F Borges; Traci R Lyons; Doris Germain; Pepper Schedin
Journal:  Cancer Res       Date:  2020-02-19       Impact factor: 12.701

3.  Sequential testicular atrophy involves changes in cellular proliferation and apoptosis associated with variations in aromatase P450 expression levels in Irs-2-deficient mice.

Authors:  Leonardo Catalano-Iniesta; Virginia Sánchez-Robledo; Maria Carmen Iglesias-Osma; Maria José García-Barrado; Marta Carretero-Hernández; Enrique J Blanco; Teresa Vicente-García; Deborah Jane Burks; José Carretero
Journal:  J Anat       Date:  2018-11-25       Impact factor: 2.610

4.  IRS1 and IRS2: molecular characterization, tissue expression and transcriptional regulation by insulin in yellow catfish Pelteobagrus fulvidraco.

Authors:  Mei-Qin Zhuo; Ya-Xiong Pan; Kun Wu; Yi-Huan Xu; Li-Han Zhang; Zhi Luo
Journal:  Fish Physiol Biochem       Date:  2016-11-18       Impact factor: 2.794

Review 5.  Insulin receptor substrates (IRSs) and breast tumorigenesis.

Authors:  Bonita Tak-Yee Chan; Adrian V Lee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-22       Impact factor: 2.673

Review 6.  The impact of transgenic IGF-IR overexpression on mammary development and tumorigenesis.

Authors:  Robert A Jones; Roger A Moorehead
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-11       Impact factor: 2.673

7.  Lactation failure in Src knockout mice is due to impaired secretory activation.

Authors:  Harriet Watkin; Monica M Richert; Andrew Lewis; Kristina Terrell; James P McManaman; Steven M Anderson
Journal:  BMC Dev Biol       Date:  2008-01-23       Impact factor: 1.978

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.